Scienjoy Holding Corporation Reports Nine Months ended September 30, 2025 Unaudited Financial Results - Scienjoy Holding (NASDAQ:SJ)

Stella-Jones (TSX:SJ) shares fell about 25% from roughly $100 earlier this year to around $75 after its latest quarterly results disappointed investors, according to the article. Net income dropped to $60 million ($1.10/share) from $1.67/share a year earlier, while revenue rose from $773 million to $791 million. The article attributes the profit decline to lower gross margin (21.7% to 19.6%) from product mix, pricing pressure, and higher input costs.

Microsoft and Meta have reduced their internal use and spending on Anthropic's Claude model. Microsoft cut its projected annual spending by over one-third, down from over $1 billion, and shifted focus to Microsoft-backed options. Meta reduced active users of Claude Code from 60,000 to 30,000 but still spent over $105 million in a recent 28-day period. According to Anthropic, two customers generate a quarter of its revenue.

Nurix Therapeutics has begun a Phase 1b/2 trial of bexobrutideg and venetoclax for CLL/SLL, part of its Roche collaboration. The study aims to inform future registration strategies and potential antibody combinations.

Nurix Therapeutics (NRIX) has enrolled the first patient in a Phase 1b/2 study of bexobrutideg combined with venetoclax for chronic lymphocytic leukemia (CLL). The trial, part of a collaboration with Roche, aims to evaluate safety, tolerability, and clinical activity. Data may inform future development strategies for CLL and other B-cell malignancies.

Bausch + Lomb (NYSE: BLCO) announced progress in developing tonabersat (BL1243) for dry age-related macular degeneration, receiving FDA endorsement for a phase 2 trial in 2027. The company's P/S ratio is 1.18x, below its historical median, and it remains unprofitable. Its GF Score is 60, reflecting mixed fundamentals with strengths in valuation and momentum but weaknesses in profitability and financial strength.

Micron (MU) will license Netlist's memory technology patents for $600M over 5 years, settling a patent dispute. The agreement resolves ongoing litigation between the two companies.